Great Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMO
Summary
Compliant with the European Union’s Annex 1 standards, the Company specializes in the production of liquid and freeze-dried parenteral drugs, distributing globally for both clinical and commercial use. “Lyocontract has an opportunity to further scale and broaden its offerings and expand its global capabilities at a time when there is growing demand for lyophilization services,” said Noah Rhodes, Managing Director and Head of Private Equity at GPP. “We look forward to leveraging our experience strengthening successful CDMOs to solidify Lyocontract’s position as a global industry leader.” “Lyocontract has a strong track record of providing highly specialized and critically important manufacturing services to pharmaceutical companies, bringing a powerful combination of experience, expertise and technological capabilities to all of its partnerships,” said David Slattery, Senior Vice President at GPP. Founded in 2007, Lyocontract GmbH is a premium independent drug product contract development and manufacturing organization (“CDMO”) based in Ilsenberg, Germany. Compliant with the European Union’s Annex 1 standards, the company specializes in producing liquid and freeze-dried parenteral drugs, which are distributed globally for both clinical and commercial applications.